US FDA approves fostemsavir for the treatment of HIV in heavily pre-treated adults with limited treatment options

Fostemsavir is a first-in-class antiretroviral designed to prevent HIV attachment to and entry into CD4+ T cells. Approval was based on a trial involving 371 patients who were heavily treatment-experienced (85% exposed to ≥5 regimens), most of whom (86%) had a history of AIDS.


US Food and Drug Administration